Sanofi's critics have launched a new offensive. After months of protesting yielded big reductions in the French drugmaker's layoff plans in its home country, those less-than-pleased with Sanofi ($SNY) are zeroing in on its decision to swap cheap Campath for the (presumably) much pricier, soon-to-be-approved multiple sclerosis drug Lemtrada.
Just weeks after Genzyme filed its application for Lemtrada as a new treatment for multiple sclerosis, regulators have handed the NDA back, telling the biologics arm of Sanofi that it needs to complete a rewrite before they can properly assess it.
The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi, is pulling the plug. Why? To prepare the way for Lemtrada, a multiple sclerosis treatment that is, essentially, Campath by another name.
The good news for U.S. cancer patients: New drugs get to market faster in the U.S. than they do elsewhere. The bad news: There's a higher price tag for that speed.
Genzyme immune-disease chief Dr. Michael Panzara patiently guided the Financial Times through a detailed review of the company's development plans for the MS drug Campath, adding in an interesting
With Sanofi-Aventis's $69-per-share offer for Genzyme set to expire January 21, the Wall Street Journal is reporting that the companies have resumed negotiations for a potential buyout offer. So far,
Just in case anyone at Sanofi-Aventis ( $SNY ) had missed his position, Genzyme ( $GENZ ) CEO Henri Termeer ( photo ) told France's Le Figaro that he would be open to linking the performance of the
Genzyme ( $GENZ ) and Sanofi-Aventis ( $SNY ) are once again trading barbs in their ongoing contest over Sanofi's hostile bid. But the most intriguing remarks about that potential deal today came from
One of the big sticking points in the potential Sanofi-Aventis/ Genzyme deal has been sales estimates for Campath, the company's leukemia drug that it's developing for multiple sclerosis. Genzyme has
We're wondering whether Genzyme's new asking price of $89 per share is the real deal--or whether it's high-balling its price tag in hopes that Sanofi-Aventis would meet it in the middle of that